Clinical Trials Logo

Clinical Trial Summary

People living with Parkinson's disease experience progressive motor and non-motor symptoms, which negatively impact on health-related quality of life. Symptoms emerge and evolve as the disease progresses. Current care models are often inadequate to meet their needs. This study aims to evaluate whether a complex and innovative model of integrated care will increase an individual's ability to achieve their personal goals, have a positive impact on health and symptom burden, and be more cost-effective when compared with usual care.


Clinical Trial Description

Background: People living with Parkinson's disease experience progressive motor and non-motor symptoms, which negatively impact on health-related quality of life and can lead to an increased risk of hospitalisation. It is increasingly recognised that the current care models are not suitable for the needs of people with parkinsonism whose care needs evolve and change as the disease progresses. This study aims to evaluate whether a complex and innovative model of integrated care will increase an individual's ability to achieve their personal goals, have a positive impact on health and symptom burden, and be more cost-effective when compared with usual care. Methods: This is a single centre, randomised controlled trial where people with parkinsonism and their informal caregivers are randomised into one of two groups: either PRIME Parkinson multi-component model of care; or usual care. Adults ≥18 years with a diagnosis of parkinsonism, able to provide informed consent or the availability of a close friend or relative to act as a personal consultee if capacity to do so is absent, and living in the trial geographical area are eligible. Up to three caregivers per patient can also take part, must be ≥18 years, provide informal, unpaid care and able to give informed consent. The primary outcome measure is goal attainment, as measured using the Bangor Goal Setting Interview. The duration of enrolment is 24 months. The total recruitment target is n=214 and the main analyses will be intention to treat. Discussion: This trial tests whether a novel model of care improves health and disease-related metrics including goal attainment, and decreases hospitalisations whilst being more cost-effective than the current usual care. Subject to successful implementation of this intervention within one centre, the PRIME Parkinson model of care could then be evaluated within a cluster-randomised trial at multiple centres. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05127057
Study type Interventional
Source University of Bristol
Contact Emily J Henderson, PhD
Phone +44 117 331 3903
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date March 1, 2022
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04876326 - Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy N/A
Enrolling by invitation NCT01453127 - DaTSCAN Imaging in Aging and Neurodegenerative Disease Phase 4
Completed NCT01174771 - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration N/A
Completed NCT03314610 - Effect of Need to Void on Parkinsonian Gait
Completed NCT00950196 - Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Phase 4
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Completed NCT01581645 - Mobilaser Study to Help With People Who Are Having Problems With Their Gait Phase 0
Not yet recruiting NCT00767546 - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Phase 1
Completed NCT02214862 - 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Phase 0
Recruiting NCT04518059 - Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Enrolling by invitation NCT01329926 - Molecular Analysis of Human Neural Stem Cells
Terminated NCT00745030 - Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism N/A
Completed NCT04222218 - Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy N/A
Completed NCT03386669 - Novel Neuroimage Study in Tauopathies With Parkinsonism Phase 2
Completed NCT02064543 - Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism
Terminated NCT03034564 - A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease Phase 4
Active, not recruiting NCT02650843 - Non-motor Symptoms and Brain Dopamine Transporter Binding
Recruiting NCT03495024 - Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Phase 4
Recruiting NCT04238000 - Cerebellar rTMS Theta Burst for Dual-task Walking in Parkinson's Disease N/A